Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis by Howlin, R. et al.
 1 
Title:  Low dose nitric oxide as targeted anti-biofilm adjunctive therapy to 1 
treat chronic Pseudomonas aeruginosa infection in cystic fibrosis 2 
 3 
Authors: Robert P. Howlin,
†,1,2,3,4
 Katrina Cathie,
†,1,2,5
 Luanne Hall-Stoodley,
6,7
 Victoria 4 
Cornelius,
8,1
 Caroline Duignan,
3,1,2
 Ray Allan,
7,1,2,5,4
 Bernadette O. Fernandez,
5
 Nicolas 5 
Barraud,
9
 Ken Bruce,
10
 Johanna Jefferies,
5,1,2,11,4  
Michael Kelso,
12
 Staffan Kjelleberg,
9,13
 Scott 6 
Rice,
9,13
 Geraint Rogers,
14,15,10
 Sandra Pink,
1,2
 Caroline Smith,
1,2
 Priya Sukhtankar,
5,7
 Rami 7 
Salib,
5,1,2,4
 Julian Legg,
1,2
 Mary Carroll,
1,2
 Thomas Daniels,
1,2
 Martin Feelisch,
1,2,4,5
 Paul 8 
Stoodley,
6,16,1,2
 Stuart C. Clarke,
5,1,2,11,4
 Gary Connett,
1,2
 Saul N. Faust,
††+7,5,1,2,4
 Jeremy S. 9 
Webb,
††3,4,1,2
  10 
 11 
†
 and 
††
 indicate equal contribution. 12 
 13 
To whom correspondence should be addressed:  14 
+
Prof Saul N. Faust 15 
NIHR Wellcome Trust Clinical Research Facility,  16 
West Wing, Mailpoint 218,  17 
University Hospital Southampton NHS Foundation Trust,  18 
Tremona Road, Southampton, SO16 6YD. 19 
s.faust@soton.ac.uk 20 
 21 
1
NIHR Southampton Respiratory Biomedical Research Unit, UK  22 
2
University Hospital Southampton NHS Foundation Trust, UK 23 
3
University of Southampton, Centre for Biological Sciences, UK 24 
4
University of Southampton, Institute for Life Sciences, UK 25 
5
University of Southampton, Faculty of Medicine, Clinical and Experimental Sciences, UK 26 
6
The Ohio State University, College of Medicine, Microbial Infection and Immunity, USA 27 
7
Southampton NIHR Wellcome Trust Clinical Research Facility, UK 28 
8
Imperial College London, School of Public Health, UK  29 
9
University of New South Wales, Centre for Marine Bio-Innovation and School of 30 
Biotechnology and Biomolecular Sciences, Australia 31 
10
Kings College London, Institute of Pharmaceutical Science, UK 32 
11
Public Health England, Southampton, UK 33 
12
University of Wollongong, Illawarra Health and Medical Research Institute and School of 34 
Chemistry, Australia 35 
13
Singapore Centre on Environmental Life Sciences Engineering and Nanyang Technological 36 
University, School of Biological Sciences, Singapore 37 
14
South Australia Health and Medical Research Institute, Infection and Immunity Theme, North 38 
Terrace, Adelaide, Australia 39 
15
Flinders University, School of Medicine, Bedford Park, Adelaide, Australia 40 
16
University of Southampton, Faculty of Engineering, National Centre for Advanced Tribology 41 
at Southampton (nCATS), UK 42 
 43 
Short Title: Low dose nitric oxide therapy in cystic fibrosis 44 
 2 
Abstract:  45 
Despite aggressive antibiotic therapy, bronchopulmonary colonisation by Pseudomonas 46 
aeruginosa causes persistent morbidity and mortality in cystic fibrosis (CF). Chronic P. 47 
aeruginosa infection in the CF lung is associated with structured, antibiotic-tolerant bacterial 48 
aggregates known as biofilms. We have demonstrated the effects of non-bactericidal, low-dose 49 
nitric oxide (NO), a signaling molecule that induces biofilm dispersal, as a novel adjunctive 50 
therapy for P. aeruginosa biofilm infection in CF in an ex-vivo model and a proof of concept 51 
double blind clinical trial. Submicromolar NO concentrations alone caused disruption of biofilms 52 
within ex-vivo CF sputum, and a statistically significant decrease in ex-vivo biofilm tolerance to 53 
tobramycin and tobramycin combined with ceftazidime. In the 12 patient randomized clinical 54 
trial, 10 ppm NO inhalation caused significant reduction in P. aeruginosa biofilm aggregates 55 
compared to placebo across the 7 days of treatment. Our results suggest a benefit of using low-56 
dose NO as adjunctive therapy to enhance the efficacy of antibiotics used to treat acute P. 57 
aeruginosa exacerbations in CF. Strategies to induce the disruption of biofilms have potential to 58 
overcome biofilm-associated antibiotic resistance in CF and other biofilm-related diseases.  59 
 60 
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Introduction 81 
Cystic fibrosis (CF) is the most common lethal, hereditary disease in Caucasian populations, 82 
with a UK and US incidence of approximately 1 in 2500 live births and an estimated worldwide 83 
prevalence of 70,000 (1, 2). Long-term morbidity and mortality is primarily associated with the 84 
effects of chronic Pseudomonas aeruginosa lung infection and the persistence of P. aeruginosa 85 
biofilms (3, 4). Bacteria in biofilms are enclosed in a self-produced biopolymeric matrix and 86 
display up to 1,000-fold higher tolerance to antibiotic challenge than their single cell, planktonic 87 
(free living) counterparts (5). Biofilms also exhibit resistance to phagocytosis and other 88 
components of the host’s innate and adaptive immune system (6). Biofilm survival mechanisms 89 
include impedance of antibiotic diffusion through the biofilm matrix (7),  altered growth or 90 
metabolic rates of bacterial subpopulations within the biofilm (8, 9), and physiological (8), 91 
biochemical (10) and genetic (11, 12) changes. In addition, sub-inhibitory levels of 92 
aminoglycoside antibiotics can enhance biofilm formation under laboratory conditions (13). 93 
Biofilms can be firmly attached to tissue but can also exist in the protected phenotype as 94 
aggregates in the mucus of the CF lung (14). Biofilms are extremely difficult to eradicate using 95 
conventional therapeutic regimes (15). New approaches targeting chronic biofilm infections are 96 
needed for more effective treatment of P. aeruginosa in CF, and other biofilm-related diseases 97 
(16).  98 
 99 
In vivo, bacteria often transition between planktonic and biofilm lifestyles. Given the correct 100 
environmental cues, biofilm bacteria undergo coordinated dispersal and reversion to the 101 
planktonic form (17). We identified a role for the signaling molecule nitric oxide (NO) in the 102 
dispersal of P. aeruginosa biofilms (18, 19) (Fig. 1).  At nanomolar concentrations, NO mediates 103 
dispersal by increasing bacterial phosphodiesterase activity with a consequent reduction of the 104 
intracellular second messenger and biofilm regulator cyclic-di-guanosine monophosphate (c-di-105 
GMP) (18, 19). Here we report the effects of non-bactericidal, low-dose NO on clinical 106 
pseudomonal biofilms ex-vivo in the laboratory using conventional and molecular 107 
microbiological methods. We have also extended our laboratory findings to a proof of concept 108 
clinical trial in humans, demonstrating a significant direct effect on pseudomonal biofilm load in 109 
CF patients treated with NO gas plus conventional intravenous antibiotic therapy compared to 110 
intravenous antibiotics alone.  111 
112 
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 113 
Fig. 1. Role of NO in disrupting antibiotic tolerance mechanisms associated with the 114 
biofilm structure. A) Biofilm tolerance mechanisms include reduced antibiotic diffusion, 115 
release of protective enzymes capable of destroying or inactivating antibiotics in the biofilm 116 
matrix and formation of physiologically distinct bacterial subpopulations (e.g. persister cells) 117 
resulting from nutrient and oxygen gradients. B) Low-dose nitric oxide diffuses into the biofilm 118 
and interacts with cell receptors that upregulate cellular phosphodiesterases (PDEs) which 119 
accelerate c-di-GMP degradation. This prevents c-di-GMP from interacting with proteins at the 120 
transcriptional, translational or post-translational level and leads to cell surface and physiological 121 
changes associated with dispersal and motility (red circle inset). C) Dispersal is accompanied by 122 
reversion of the bacteria to a planktonic phenotype that renders them more susceptible to 123 
antibiotic-mediated killing (18, 19). 124 
  125 
 5 
Results  126 
 127 
Nitric oxide induces P. aeruginosa biofilm dispersal in human CF sputum samples  128 
NO-induced dispersal of P. aeruginosa biofilms was specifically measured directly in 129 
expectorated sputum samples from 5 CF patients using fluorescence in situ hybridization (FISH). 130 
A significant reduction in mean biofilm thickness was observed upon treatment with 450 nM NO 131 
(generated from the spontaneous NO-donor sodium nitroprusside, SNP; see Methods) and P. 132 
aeruginosa biofilm microcolonies (aggregates typically ~15 µm in diameter) were visibly 133 
disrupted by NO in 5/5 patient samples. Fig. 2A shows representative experiments from 3 134 
different patients: Sample 1(p=0.003), Sample 2 (p=0.029), and Sample 3 (p=0.029).  135 
 136 
Nitric oxide mediated dispersal of CF P. aeruginosa isolates occurs within 5 to 10 hours  137 
Addition of NO (in the form of the NO-donor sodium nitroprusside, SNP) to 12 biofilm-forming 138 
P. aeruginosa clinical isolates from CF sputum samples consistently caused dispersal leading to 139 
steep increases in the optical density (turbidity) of planktonic bacterial suspensions overlying 140 
biofilms after 5 hours (Fig. 2B). The increase in OD correlated with a decrease in biofilm 141 
biomass from surfaces of plate wells as determined by fluorometric measurements and confocal 142 
microscopy, confirming the dispersal effect of NO (Figs. 2D, E). Biofilm dispersal was 143 
confirmed to be NO-specific using the NO scavenger PTIO, which reduced the dispersal of P. 144 
aeruginosa induced by SNP (p=0.002) to levels similar to the control treatment (Fig. 2C). 145 
Treatment of biofilms with potassium ferricyanide (as a control for NO-independent breakdown 146 
products of SNP) had no dispersal effect compared with untreated biofilms (p=0.394; Fig. 2C). 147 
Dispersal was observed at NO concentrations as low as 450 pM, peaking at 450 nM (Fig. 2B), 148 
with higher concentrations of NO (4.5 µM) showing reduced efficacy for biofilm dispersal (Fig. 149 
2B). NO at a concentration of 450 nM dispersed all 12 biofilm-forming CF clinical isolates 150 
tested.  151 
 152 
  153 
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 154 
Fig. 2. A) Direct measurement of NO-induced P. aeruginosa biofilm dispersal in 155 
expectorated CF sputum samples. Image analysis shows a significant reduction in mean P. 156 
aeruginosa biofilm thickness following treatment of CF sputum samples from 3 different 157 
patients (Samples 1, 2 & 3) with 450 nM NO, compared with buffer alone (untreated) 158 
(*represents a statistically significant difference between data medians, P = 0.02). P. aeruginosa 159 
was identified using fluorescence in situ hybridisation (FISH) with both a Cy3-labeled P. 160 
aeruginosa specific 16S rRNA probe (green) and a Cy5-labelled eubacterial 16S probe (red).  161 
Confocal laser scanning microscopy (CLSM) images show a reduction of P. aeruginosa (yellow 162 
due to hybridisation with both probes) in biofilms. Images show horizontal xy (top-down view) 163 
sections and flanking images show vertical z (side view) CSLM sections of untreated (left) and 164 
NO-treated (right) CF sputum samples. Scale bar = 25 µm. B) Nitric oxide (NO) disperses in 165 
vitro biofilms grown from biofilm-forming P. aeruginosa CF clinical isolates. Dispersal of 166 
biofilm bacteria into the planktonic phase (measured by mean optical density (OD) of overlying 167 
planktonic suspensions) following treatment of a clinical isolate P. aeruginosa biofilm with low-168 
dose NO (9 pM-4.5 µM) derived from the spontaneous NO donor, SNP. Depicted recordings are 169 
from a single isolate and representative of qualitatively identical data from 12 P. aeruginosa 170 
isolates studied. C) Biofilm dispersal is NO-dependent. Mean OD measurements of planktonic 171 
bacteria following 15 h treatment of P. aeruginosa biofilms with SNP alone, SNP in the presence 172 
of the NO scavenger PTIO, or with potassium ferricyanide alone (PFc); *represents a statistically 173 
significant difference between data medians, P = 0.02). Data from 3 experiments with 4 wells per 174 
experiment. D) Dispersal causes biofilm detachment from the base of tissue-culture plate 175 
wells indicated by loss of fluorescence after NO treatment, compared with untreated 176 
controls. Residual biofilms were fluorescently-labelled with the nucleic acid probe, Syto9. Scale 177 
indicates fluorescence intensity, with red corresponding to the highest concentration of surface-178 
attached P. aeruginosa and blue-purple to the fewest remaining attached bacteria. E) NO 179 
induces dispersal of P. aeruginosa biofilms in vitro. Representative CSLM images indicate 180 
reduced P. aeruginosa in biofilms from CF isolates following NO treatment compared with 181 
untreated biofilms. Each image shows horizontal xy (top-down view) CLSM sections (square), 182 
and flanking images show vertical z (side-view) CLSM sections after staining biofilms with the 183 
BacLight Live (green)/Dead (red) kit. Scale bar = 25 µm. 184 
 7 
Nitric oxide potentiates antibiotics to disrupt and kill clinical P. aeruginosa biofilms  185 
P. aeruginosa clinical isolate biofilms treated with the antibiotic tobramycin alone or with 186 
tobramycin/ceftazidime combinations were compared to biofilms treated with NO alone, a 187 
combination of NO and tobramycin or a combination of NO, tobramycin and ceftazidime (Fig. 188 
3). Remarkably, the biomass and thickness of the P. aeruginosa biofilm increased substantially 189 
following antibiotic treatments in the absence of NO.  Compared with untreated biofilms, an 190 
increase in biofilm biomass and biofilm thickness was observed following tobramycin treatment 191 
alone (biofilm biomass: 243% increase compared to control, p=0.028, Fig. 3B; and mean biofilm 192 
thickness: 199% increase compared to control, p=0.065, Fig. 3C) and the tobramycin/ceftazidime 193 
combination (biofilm biomass: 155% increase compared to control, p=0.04, Fig. 3B; and mean 194 
biofilm thickness: 174% increase compared to control, p=0.04, Fig. 3C). Viability staining 195 
demonstrated that predominantly live (green) cells remained within the core of the biofilm 196 
structures (Fig. 3A). While biofilm bacteria tolerated the antibiotic treatments at the 197 
concentrations used (10 M), free-living bacteria within the planktonic phase remained 198 
susceptible (Fig. 3D).   199 
 200 
Adjunctive NO used in combination with 5 μg ml-1 tobramycin (with or without ceftazidime) 201 
demonstrated a pronounced and significant reduction in P. aeruginosa mean biofilm biomass and 202 
thickness compared with both untreated biofilms and biofilms treated with antibiotics in the 203 
absence of NO (p=0.001) (Figs. 3B & 3C). Residual surface-attached biofilms observed by 204 
CSLM appeared as only a thin monolayer indicating that the majority of the remaining surface-205 
attached P. aeruginosa had been killed, shown in Fig. 3A by increased red fluorescent staining 206 
with propidium iodide. In addition, there was a marked reduction in viable planktonic cells 207 
following adjunctive NO treatments (Fig. 3D), demonstrating that bacteria released from 208 
biofilms during NO-induced dispersal are killed in the planktonic phase by the combined 209 
antibiotic treatment.  210 
 211 
  212 
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 213 
 214 
Fig. 3. Antibiotic efficacy against P. aeruginosa clinical isolate biofilms is enhanced in the 215 
presence of low-dose NO. A) Representative confocal laser scanning microscopy (CLSM) 216 
images showing surface-attached P. aeruginosa following treatment with: buffer alone 217 
(untreated); NO alone; MBC antibiotics (5 μg ml-1 tobramycin with or without 5 μg ml-1 218 
ceftazadime); or antibiotics combined with NO. Images show horizontal xy (top-down view) 219 
sections and flanking images show vertical z (side view) CSLM sections. Biofilms were stained 220 
with BacLight Live (green)/Dead (red) kit to indicate viable cells. Scale bars = 25 µm. B) Image 221 
analysis of CLSM images of residual P. aeruginosa biofilms with adjunctive NO shows a 222 
reduction in mean total biomass (Fig. 3B) and biofilm thickness (Fig. 3C) following treatment 223 
with antibiotics (tobramycin alone and tobramycin (Tob)/ceftazidime (Ceft) combined) 224 
indicating that NO-treatment reduces the amount of remaining biofilm bacteria (error bars 225 
represent standard error of the mean of 5 different microscopic fields). An increase in biofilm 226 
biomass and biofilm thickness is shown following tobramycin treatment alone (biofilm biomass: 227 
243% increase compared to control, p=0.028, Fig. 3B; and mean biofilm thickness: 199% 228 
increase compared to control, p=0.065, Fig 3C) and the tobramycin/ceftazidime combination 229 
(biofilm biomass: 155% increase compared to control, p=0.04, Fig. 3B; and mean biofilm 230 
thickness: 174% increase compared to control, p=0.04, Fig 3C). Viable P. aeruginosa in the 231 
dispersed population (planktonic suspension), determined by colony forming unit (CFU) counts 232 
of P. aeruginosa following antibiotic treatment of biofilms with or without NO, indicate that 233 
combined NO treatment leads to killing of the bacteria released from the biofilm (Fig. 3D).  234 
 9 
 A proof of concept randomized trial demonstrates low-dose nitric oxide adjunctive therapy 235 
reduces detectable P. aeruginosa biofilm in patients without increasing planktonic bacterial 236 
loads 237 
12 patients were randomized to receive either low-dose NO inhalation or placebo (CONSORT 238 
diagram, figure 4). Adjunctive NO used in combination with tobramycin and ceftazidime 239 
demonstrated a significant reduction in the key primary microbiological endpoint,  P. aeruginosa 240 
biofilm aggregates. This is shown in aggregates both over 20 cells in size and in those over 10 241 
cells in size compared to those receiving placebo with antibiotics over the 7 days of treatment  242 
(GEE analysis, p=0.031 and p=0.029 respectively for days 5 and 7; and Fig. 5). Data suggested 243 
less P. aeruginosa biofilm as quantified by both the number and volume of aggregates greater 244 
than 20 or 10 cells in the NO group compared with placebo through day 7 while on NO therapy. 245 
This reduction was not fully maintained after treatment was stopped, as pseudomonal biofilm 246 
was detected in treatment group samples at timepoint 10-13 days following the cessation of NO 247 
therapy (study period days 5 through 20, Table 1 and Fig 5). See methods for rationale regarding 248 
cluster size selection. Other important secondary endpoints are shown in Table 2. From an 249 
individual participant safety perspective, there was no evidence that the biofilm dispersal 250 
increased the amount of viable P. aeruginosa detected in planktonic phase by CFUs.  qPCR, 251 
indicative of total viable P. aeruginosa cells (20), did not demonstrate a difference between 252 
groups due to the small numbers and large variation between individuals.   There were also no 253 
adverse clinical safety signals (FEV1, FVC, quality of life score) in the treatment group 254 
compared to those treated with placebo. Baseline clinical data are shown in Table 3, baseline 255 
laboratory data and study adverse effects are shown in Supplementary Tables S1 and S2, and 256 
individual patient data for the primary outcome (FISH) and one clinical parameter (FEV1) are 257 
shown in Supplementary Table S3. 258 
 259 
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 298 
Figure 4: Clinical Study CONSORT diagram depicting the flow of patients through the study. 299 
In order for patients to be randomised they had to be admitted during pulmonary exacerbation to 300 
receive trial therapy concurrently with IV antibiotics.  301 
Analysed (n=6) 
Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to Nitric Oxide (n=6) 
Received allocated intervention (n=6) 
Did not receive allocated intervention (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to placebo (n=6) 
Received allocated intervention (n=6) 
Did not receive allocated intervention (n=0) 
Analysed (n=6) 
Excluded from analysis (n=0) 
 
Assessed for eligibility (n=79) Excluded (n=44) 
 Not meeting inclusion criteria (n=21) 
 Declined to participate (n=15) 
 Other reasons (n=8) e.g. allergic to 
study antibiotics 
Excluded (n=14) 
 No detectable PA in sputum (n=13) 
 Other reasons  (n=1) 
 
Randomized (n=12) 
Not randomized (n=9) 
 Did not exacerbate during the study 
period (n=8) 
 Declined randomisation at time of 
pulmonary exacerbation (n=1) 
Screened (n=35) 
Enrolled (n=21) 
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 313 
Fig. 5. Reduction in P. aeruginosa biofilm with NO adjunctive therapy. Representative FISH 314 
confocal images from a CF patient being treated with NO adjunctive to conventional 315 
antimicrobial agents (ceftazadime and tobramycin) compared to a patient on antibiotics alone 316 
(n=6 in both nitric oxide and placebo groups). Almost no P. aeruginosa biofilms were detectable 317 
in the treatment group compared to placebo. At follow up, 10-13 days after NO adjunctive 318 
treatment stopped, pseudomonal biofilm was detected in sputum having been reduced while on 319 
NO. Scale bars = 25 µm. The central panels show x-y plan views of merged image stacks (total 320 
biofilm detected in 3D imaging), the rectangular z-axis side panels show representative single 321 
side views of the biofilm (21)  322 
 323 
 324 
 325 
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Tables 1-2. Results from randomized clinical trial. 327 
 328 
Table 1: Primary outcome results: showing mean differences between groups (NO or placebo) of 329 
change from baseline 330 
 331 
 332 
333 
  Change from baseline, Mean (SD) 
Treatment effect: mean difference (95%CI), 
p value 
Day 5 7 10 20 
Intervention period 
(days 5 &7) 
Study period 
(days 5,7,10 & 20) 
FISH: Ln number of aggregates  > 20 cells 
Placebo 
0.11 
(2.38) 
0.35 
(1.44) 
0.38 
(2.32) 
NA 
3.49 (0.32, 6.67) p= 0.031 1.35 (-0.58, 3.7) p=0.170 
NO 
-4.33 
(5.11) 
-2.19 
(3.93) 
0.98 
(1.83) 
NA 
FISH: Ln volume of aggregates  > 20 cells 
Placebo 
-0.16 
(2.51) 
-0.03 
(1.54) 
0.21 
(2.20) 
NA 
4.47 (-0.40,8.98) p= 0.052 2.35 (0.08, 4.63) p=0.043 
NO 
-6.10 
(7.50) 
-3.03 
(5.88) 
0.97 
(2.02) 
NA 
FISH: Ln number of aggregates  > 10 cells 
Placebo 
0.28 
(2.09) 
0.26 
(1.52) 
0.20 
(2.04) 
NA 
2.44 (0.25, 4.62) p=0.029 1.09 (-0.54, 2.72) p=0.118 
NO 
-1.46 
(1.08) 
-2.71 
(4.56) 
1.10 
(1.19) 
NA 
FISH: Ln volume of aggregates  > 10 cells 
Placebo 
0.08 
(2.33) 
0.05 
(1.50) 
-2.47 
(2.12) 
NA 
2.68 (-.052, 5.41) p=0.055 1.27 (-0.62, 3.16) p=0.188 
NO 
-1.75 
(1.14) 
-3.37 
(6.34) 
1.07 
(1.50) 
NA 
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Table 2. Microbiological and clinical safety monitoring: showing mean differences between 334 
groups (NO or placebo) of change from baseline 335 
 336 
 337 
 338 
  
Change from baseline,  
Mean (SD) 
Treatment effect, mean  
(95%CI); p value 
Day 5 7 10 20 
Intervention period  
(days 5 &7) 
Total study period  
(days 5,7,10 & 20) 
     Ln CFU 
Placebo 
-1.62 
(2.34) 
-2 
(3.77) 
-0.89 
(4.08) 
NA 
-0.19 (-2.95, 2.56) p=0.891 0.03 (-2.53, 2.59) p=0.980 
NO 
-1.97 
(2.20) 
-1.25 
(2.76) 
-1.30 
(1.64) 
NA 
    Ln QPCR 
Placebo 
-2.16  
(1.73) 
-4.33  
(2.44) 
-4.32  
(1.92) 
NA 
-0.47 (-1.91, 0.97) p=0.519 -0.37 (-1.44, 0.71) p=0.504 
NO 
-1.86  
(1.60) 
-3.67  
(1.81) 
-3.09  
(1.74) 
NA 
 
 
Change from baseline,  
Mean (SD) 
Treatment effect, mean  
(95%CI); p value 
 Day 5 7 10 20 
Intervention period 
(day 7 only) 
Study period 
(day 20 only) 
    FEV1 
Placebo NA 
6.67 
(4.46) 
9.00 
(2.52) 
6.17 
(3.49) 
-8.93 (-25.3, 7.42) p=0.248 1.95 (-7.31, 11.20) p=0.645 
NO NA 
15.6 
(17.2) 
5.01 
(14.2) 
4.22 
(9.35) 
    FVC 
Placebo NA 
4.83 
(6.74) 
9.17 
(5.46) 
6.33 
(4.46) 
-11.6 (-30.7, 8.42) p=0.229 8.03 (-4.10, 20.2) p=0.168 
NO 
NA 
16.0 
(20.1) 
3.75 
(14.6) 
-1.70 
(12.3) 
   339 
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Table 3: Baseline clinical characteristics of groups (A=Nitric Oxide, B=Placebo)  340 
 341 
  342 
  T
re
a
tm
en
t 
G
ro
u
p
 
N
 
 M
ea
n
 
S
td
. 
D
ev
ia
ti
o
n
 
Age in years A 6 30.0 13.99 
B 6 29.3 15.60 
Height in cm  A 6 162.8 9.45 
B 6 166.0 9.27 
Weight in kg  A 6 56.4 9.61 
B 6 63.0 8.32 
Heart rate in bpm  A 6 89.3 18.62 
B 6 91.2 17.19 
Systolic blood pressure 
(mmHg)  
A 6 107.3 13.84 
B 6 121.0 14.97 
Diastolic blood pressure 
(mmHg)  
A 6 64.2 9.37 
B 6 75.8 13.73 
Oxygen saturation  
(% in air)   
A 6 95.2 2.23 
B 6 95.2 3.25 
Respiratory rate 
 (per minute)  
A 6 20.0 1.10 
B 6 18.5 2.17 
Temperature (deg C)  A 5 36.8 .31 
B 6 36.9 .48 
FEV1% of predicted (l) A 6 40.2 20.14 
B 6 45.7 18.28 
FVC % of predicted (l) A 6 54.4 17.60 
B 6 71.5 21.11 
Average exhaled NO levels (in 
ppb)  
A 6 12.7 9.46 
B 6 9.3 8.86 
 15 
Circulating NO metabolites change little during low-dose NO inhalation in CF patients 343 
Plasma nitrate (NO3
-
) concentrations tended to increase in response to delivery of low-dose NO, 344 
but these changes did not reach statistical significance (P > 0.05). Plasma levels of nitrite (NO2
-
) 345 
and total nitrosation products (RXNO) paradoxically decreased during NO inhalation, although 346 
this was also not significant. With the exception of unusually high nitrite levels in erythrocytes 347 
compared to plasma values there was also no obvious effect of inhaled NO on NO metabolite 348 
status in these blood cells, which is surprising given that nitrosylhemoglobin (NO-Heme) is the 349 
most sensitive marker of NO availability in vivo and nitrate is the final oxidation product of NO 350 
(22) (thus, both might be expected to be elevated following prolonged NO inhalation). Direct NO 351 
measurement in sputum was impractical due to the short half-life of NO in relation to the time 352 
taken for the probe to equilibrate in individual sputum samples (data not shown). Overall, 353 
determination of a comprehensive panel of NO metabolites suggested that low-dose inhaled NO 354 
does not significantly affect circulating NO metabolites in CF (Supplementary Figure S1).  355 
 356 
 357 
 358 
 359 
 360 
 361 
362 
363 
364 
365 
366 
367 
368 
  369 
370 
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Discussion  371 
 372 
Targeted therapy to address biofilm infection, rather than using conventional antibiotics alone, 373 
represents a potential paradigm shift in the treatment of chronic pseudomonal infection in cystic 374 
fibrosis.  Our experiments show that adjunctive NO can disrupt P. aeruginosa biofilms and 375 
suggest a novel approach to the challenge of managing persistent Pseudomonas biofilm infection 376 
in CF patients. 377 
 378 
The importance of the biofilm phenotype in promoting P. aeruginosa survival and persistence 379 
within the lower respiratory tract is well established (4, 23). However, there are currently no 380 
clinically recognized therapeutic approaches for eradicating established biofilm-associated P. 381 
aeruginosa respiratory infections. New treatment strategies for bacterial biofilms are a critical 382 
unmet need (24-26).  383 
 384 
Our approach was to design a clinical diagnostic platform that could be used to detect changes in 385 
Pseudomonas biofilm from patients with CF. We used fluorescence in situ hybridization (FISH) 386 
as a primary technique to identify biofilm in clinical samples as recommended by the European 387 
Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the diagnosis 388 
and treatment of biofilm infections (26) . We first used ex vivo samples from CF patients to 389 
establish the diagnostic platform. We tested P. aeruginosa clinical isolates growing in biofilms 390 
and used FISH to follow the effects of NO on aggregate size in these biofilms. We designed the 391 
proof of concept clinical study to determine whether changes in the size of Pseudomonas biofilm 392 
aggregates taken from patients who had been given low dose NO could be detected during and 393 
following treatments regimes.  394 
 395 
Ex-vivo studies demonstrated that low concentrations of NO (<500 nM) significantly reduced the 396 
amount of P. aeruginosa biofilm aggregates in CF sputum, potentiating the effect of the 397 
aminoglycoside antibiotic tobramycin alone and in combination with the third generation 398 
cephalosporin ceftazidime.  399 
 400 
In addition, our results suggest that adjunctive low-dose nitric oxide might prevent a previously 401 
reported potential biofilm-enhancing effect of aminoglycoside treatment (13). Our ex-vivo data 402 
show that treatment of CF P. aeruginosa biofilms with clinically relevant concentrations of 403 
tobramycin can lead to increased biofilm growth. Bacteria in biofilms within the CF lung are 404 
likely to be exposed to sub-inhibitory concentrations of antibiotics due to poor penetration or 405 
diffusion gradients through the biofilm (27). Such sub-inhibitory antibiotic concentrations may 406 
explain the apparently paradoxical increase in biofilm thickness we observed despite increased 407 
cell death. It is possible that initially low antibiotic concentrations within the biofilm induce 408 
bacterial growth and/or extracellular matrix production, followed by increased cell death as the 409 
antimicrobial concentration increases due to diffusion into the biofilm. An alternative 410 
explanation for the increased biofilm thickness might be enhanced cell lysis, which has been 411 
shown to contribute to P. aeruginosa extracellular matrix production (28). Importantly, 412 
irrespective of mechanism, the observed enhancement of P. aeruginosa biofilm growth in the 413 
presence of tobramycin, was completely eliminated in the presence of 450 nM adjunctive NO. 414 
Nitric oxide potentiated the effect of tobramycin alone, and ceftazidime and tobramycin in 415 
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combination, by dispersing P. aeruginosa biofilms and facilitating the killing of dispersed 416 
bacteria.  417 
 418 
The proof of concept clinical study demonstrated a significant direct effect on pseudomonal 419 
biofilm (as measured by a reduction in P. aeruginosa aggregate load) in CF patients treated with 420 
NO gas plus conventional IV antibiotic therapy compared to IV antibiotics alone. The effect was 421 
not sustained following the end of NO therapy in this group of adult patients with long term 422 
chronic disease. In this small study we did not detect any side effects as a result of this treatment 423 
strategy. All changes in the clinical parameters measured favored NO treatment and there was no 424 
evidence that NO treatment caused an increase in overall bacterial load or the severity of acute 425 
exacerbations. We saw no treatment effects suggestive of NO induced vasodilatation (i.e. no 426 
increase in oxygen saturations during treatment); and no adverse effects during the weaning 427 
period at the end of each day’s NO therapy that might have been indicative of rebound 428 
pulmonary hypertension. Our study measured clinical parameters to ensure safety but not clinical 429 
efficacy, which will be the subject of future large clinical trials. 430 
 431 
Previous studies have shown that P. aeruginosa cells can be killed directly by high doses of NO 432 
(29). This might be the result of several possible toxic effects of NO on bacteria at high 433 
concentrations, including direct modification of membrane proteins, DNA cleavage and lipid 434 
peroxidation through mechanisms of both nitrosative and oxidative stress (30-32). The use of 435 
high dose NO in this way has potential cytotoxic and other adverse clinical effects (33) and is 436 
associated with considerable cost. Despite this, recent trials of high dose 160 ppm inhaled NO in 437 
CF  did not demonstrate any adverse safety signals (34, 35). In terms of biofilm growth which 438 
has not been measured in previous clinical trials, high levels of NO might result in increased 439 
nitrate levels in CF sputum that may support growth of P. aeruginosa by metabolism based on 440 
anaerobic denitrification (36, 37).  Our previous in vitro studies have shown that higher 441 
concentrations of NO can stimulate biofilm formation (18). These studies agree with another 442 
report suggesting that higher dose NO may in fact enhance aminoglycoside tolerance by 443 
blocking energy-dependent phases of drug uptake (38). The low-dose, signal-relevant 444 
concentrations of NO we used in the proof of concept clinical trial reported here are 445 
approximately three orders of magnitude lower than those shown to inhibit drug uptake and did 446 
not inhibit tobramycin efficacy against dispersed (planktonic) or biofilm P. aeruginosa bacteria. 447 
 448 
The rationale for our approach using NO to treat P. aeruginosa  infection was to exploit our 449 
discovery that low-dose NO (10 ppm, assumed to translate into submicromolar concentrations 450 
locally) mediates biofilm dispersal through increased bacterial phosphodiesterase activity and an 451 
associated decrease in c-di-GMP levels (19). We have previously shown that low-dose NO can 452 
increase the motility of P. aeruginosa cells in-vitro (18), and proposed that this increased 453 
motility promotes biofilm dispersal. In contrast and in the context of CF sputum, other studies 454 
have shown that P. aeruginosa isolates are frequently non-motile  (39) and that sputum can 455 
repress P. aeruginosa flagellar activity and motility (40, 41). Cyclic-di-GMP binds to a broad 456 
range of effector components that control the physiology, development, stability, cell 457 
adhesiveness and motility of the biofilm phenotype. Factors other than motility could therefore 458 
be responsible for biofilm disruption and a reduction in tolerance to antibiotic treatment. Further 459 
studies are required to understand the specific c-di-GMP effectors responsible for NO-mediated 460 
disruption of biofilms within CF sputum.  461 
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 462 
Chronic CF infections are often associated with multiple bacterial pathogens and complex 463 
microbial communities (42, 43). Genes that modulate c-di-GMP turnover are widely distributed 464 
in bacteria, and NO-mediated dispersal has now been observed across a number of species 465 
including many pathogenic organisms (44, 45). NO-mediated alteration of intracellular c-di-466 
GMP levels is therefore an important new potential target to control multispecies bacterial 467 
communities in CF.  NO might also be of benefit in treating younger CF patients after initial 468 
infection with P. aeruginosa. Used in these circumstances it might increase the effectiveness of 469 
eradication therapy and delay the onset of chronic biofilm infection with this organism. 470 
 471 
Our clinical trial data appear to differ from the reported effects of inhaled NO on circulating NO 472 
metabolite levels in infants with pulmonary hypertension (46), where a clear increase in NO 473 
metabolite levels was reported to occur with twice the concentration of inhaled NO used in our 474 
study. There is a paucity of information on circulating levels of NO metabolites in CF. 475 
Nevertheless, our observations are in general agreement with the notion that NO concentrations 476 
are lower in the exhaled breath of CF patients while systemic NO production does not appear to 477 
be compromised (47). Possible mechanisms for this include accelerated degradation as a result of 478 
increased oxidative stress in epithelial cells, increased NO consumption by bacterial biofilms, or 479 
impaired gas exchange as a result of mucus obstruction. All of these factors would be expected 480 
to prevent exogenous inhaled NO to reach the systemic circulation, limiting its effects to the site 481 
of administration.  482 
 483 
The main limitation of the clinical component of our study is the small sample number and 484 
between-patient variation in clinical and microbiological parameters. This has made formal 485 
statistical analyses difficult but we were able to incorporate repeated measurements over time to 486 
improve power. Variability in the qPCR results between NO and placebo groups was probably 487 
due to sample heterogeneity in chronically infected patients. Despite these limitations, FISH 488 
image analysis data demonstrate a treatment effect and provide proof of concept for our low-dose 489 
NO approach. Similarly, our analysis of the changes in systemic NO status following low-dose 490 
NO inhalation is likely compounded by inter-individual differences in NO processing. However, 491 
the lack of an observed rise in blood nitrate and NO-heme levels are consistent with well-492 
documented perturbations in NO production and handling in CF patients (48, 49). 493 
Our study has demonstrated the potential for the use of low dose NO to enhance the antibiotic 494 
treatment of biofilm infections. Although the practical challenges in delivering inhaled NO gas to 495 
CF patients were considerable, future novel NO donor antibiotics might prove to be a more 496 
feasible approach to targeting biofilms (50).  Biofilm-related chronic infections are responsible 497 
for at least half a million deaths per year at an estimated cost of over $94 billion in the United 498 
States alone (16).  More effective anti-biofilm therapies are needed to address this significant 499 
unmet need. 500 
  501 
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Materials and Methods 502 
 503 
CF sputum collection and P. aeruginosa isolation 504 
Sputum samples (51, 52) from 72 patients with CF  (median age at informed consent 21 years, 505 
range 17-62; UK NHS Research Ethics Reference 08/H0502/126) were obtained by CF 506 
physiotherapist-assisted sample expectoration. For isolation of P. aeruginosa from sputa, 507 
samples were digested using Mucolyse (Pro-Lab Diagnostics) containing dithiothreitol and 508 
phosphate buffer for 15 minutes at 37 °C, followed by culture on P. aeruginosa-specific 509 
cetrimide agar (Sigma-Aldrich). Multiplex PCR was used to confirm P. aeruginosa as previously 510 
described (53). Because P. aeruginosa colonisation of the CF lung often consists of multiple 511 
clonal lineages (54), colony sweeps (sterile loops drawn across a confluent streak of bacterial 512 
growth on cetrimide agar) were used in preference to single colony isolates for routine subculture 513 
and biofilm growth of P. aeruginosa.   514 
 515 
Nitric-oxide mediated dispersal of clinical P. aeruginosa isolates 516 
We first evaluated the ability of NO at different doses to disperse clinical isolates of P. 517 
aeruginosa biofilms in-vitro and within sputum from CF patients. Biofilm forming P. aeruginosa 518 
clinical isolates (n=12) were inoculated using overnight cultures  grown in M9 minimal medium 519 
(20 ml per litre of 20 % glucose, 2 ml per litre of 1 M MgSO4 and 100 µl per litre of 1 M CaCl2). 520 
Overnight cultures were diluted to give optical density readings corresponding to 10
6
 cells per 521 
millilitre and 200 µl aliquots were inoculated into a 96 well plate and incubated at 37 °C for 24 522 
hours. The medium was aspirated and replaced with fresh M9 medium with/without increasing 523 
concentrations of the NO-donor sodium nitroprusside (SNP), concentration range 9 pM - 4.5 µM  524 
(Sigma Aldrich). The concentration of NO produced by SNP was calculated using a NO 525 
microsensor (Unisense, Denmark) and calibrated over a range of 250 nM to 10 µM using 526 
previously published methods (55). Based on the measured linear relationship between 527 
micromolar concentration of SNP  producing nanomolar concentrations of NO (where y = 528 
0.9022x, (R
2
 = 0.9617, n=6 data points)), NO concentrations were calculated to be nearly 1000 529 
fold less than the starting concentration of SNP, resulting in approximately 450 nM NO 530 
generated from 500 µM SNP. To confirm that effects were specific to NO, assays were also 531 
carried out with SNP (500 µM) in the presence of 5 mM NO scavenger carboxy-2-phenyl-532 
4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (carboxy-PTIO; Sigma-Aldrich). M9 medium 533 
containing 500 µM potassium ferricyanide (Sigma-Aldrich), used to generate breakdown 534 
products of SNP (56, 57), was also used as a control. Optical density measurements of the 535 
supernatant containing planktonic cells were made using a BMG Labtech Omega plate reader 536 
(620 nm and chamber temperature of 37 °C) over 24 hours with measurements taken every 15 537 
minutes. Experiments were repeated 3 times with 4 replicates for each experiment. 538 
 539 
Nitric-oxide mediated dispersal of P. aeruginosa biofilms in CF sputum and antibiotic 540 
sensitivity testing  541 
The use of fluorescence in situ hybridisation (FISH) to identify microbial biofilms in situ is 542 
recommended within the European Society of Clinical Microbiology and Infectious Diseases 543 
(ESCMID) guidelines for the diagnosis and treatment of biofilm infections (26). Expectorated 544 
sputum samples (n=5) were divided in half (v/v) and treated for 15 hours with either Hanks 545 
Buffered Salt Solution (HBSS; Sigma-Aldrich) alone or HBSS containing 450 nM NO (i.e. 500 546 
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µM SNP). Samples were fixed in freshly prepared 4 % paraformaldehyde in phosphate-buffered 547 
saline (PBS) at 4 ºC and washed with PBS and PBS-ethanol (1:1 v/v) and 20 µl drops of sputum 548 
were spotted onto poly-L-lysine (PLL) coated slides and left to dry overnight. P. aeruginosa 549 
detection was performed using FISH with the 16S ribosomal probe sequences: PseaerA, 5’-550 
GGTAACCGTCCCCCTTGC-3’, specific for P. aeruginosa (58), labelled with Cy3 and 551 
EUB338 5’- GCTGCCTCCCGTAG GAGT-3’ (Domain bacteria) (59), labelled with Cy5 552 
(Integrated DNA Technologies Inc, Leuven, Belgium). Hybridization conditions for FISH were 553 
optimised and stringently evaluated in vitro to ensure specificity of the PseaerA probe. We 554 
independently confirmed the previously reported optimal hybridization conditions for the 555 
specificity of the Pseaer probe for P. aeruginosa (21, 58). Hybridisation with the sample was 556 
carried out using 20% formamide, and a 2 hour incubation at 46 ºC was followed by washing for 557 
15 minutes at 48 °C  in pre-warmed wash buffer as previously described (58, 60). Cover slips 558 
were placed on samples and imaged using an inverted Leica DMI600 SP5 confocal laser 559 
scanning microscope (CLSM; Leica Microsystems, Cambridge, U.K.). Control experiments with 560 
both positive and negative controls demonstrated that low concentrations of NO in the 561 
concentration range used for our studies did not interfere with the eubacterial or species-specific 562 
FISH signal for P. aeruginosa including no fluorescence quenching in the presence of NO  563 
(Supplementary Figure S2). 564 
 565 
P. aeruginosa biofilms were examined for antibiotic sensitivity using adjunctive treatment of 566 
450 nM NO with or without the aminoglycoside tobramycin. The antibiotic was added alone or 567 
in combination with the cephalosporin ceftazidime (both antibiotics at the minimum bactericidal 568 
concentrations (MBC) to induce killing of planktonic cells, determined to be 5 μg ml-1). Biofilms 569 
were grown from colony sweeps as described above in culture plates (MatTek Corporation, 570 
Ashland, MA, USA) and treatment carried out for 15 hours at 37 °C.  Ceftazidime is not used 571 
alone to treat CF exacerbations due to the emergence of resistant bacterial strains and so was 572 
used only in combination with tobramycin in this study. Viable bacterial cell counts were 573 
determined on cetrimide agar and residual surface bound biofilms were examined using CLSM 574 
and the Baclight Live/Dead viability stain (Invitrogen).  575 
 576 
Proof of concept randomized clinical trial 577 
We subsequently conducted a randomized, participant and outcome-assessor blind, placebo 578 
controlled, proof of concept study of inhaled NO gas in hospitalized participants aged 12 and 579 
above with CF and chronic pseudomonas colonisation between August 2011 and September 580 
2012 (UK NHS REC 11/H0502/7, EudraCT 2010-023529-39, ClinicalTrials.gov NCT02295566) 581 
(CONSORT diagram Fig. 4). 582 
Study design and placebo 583 
The design for proof of concept was randomized and placebo controlled, where participants and 584 
primary outcome assessors were blind to the treatment group. Participants randomized to the 585 
placebo arm of the trial received medical air (BOC, UK) or medical air/oxygen blend according 586 
to clinical need (determined by oxygen saturation monitoring as per standard clinical practice). 587 
This was administered through nasal cannula in the same manner as the nitric oxide so that 588 
participants did not know whether they received the trial treatment or placebo, including pre-589 
defined sham weaning procedures.  590 
 591 
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 593 
 594 
Sample size and end of study 595 
The primary aim of this study was to gain evidence that NO could reduce the proportion of 596 
aggregated bacteria in biofilms (with regards to reduction in surface area and reduction in 597 
average colony size) in the sputum of participants treated with NO. In order to demonstrate that 598 
the treatment with NO is better than the control we calculated the sample size required to achieve 599 
a 90% probability of observing the correct ordering (consistent with a treatment effect) of the 600 
proportion of bacteria in biofilms for each group (estimated taking into account the results 601 
observed from the laboratory experiments) (61).  It was estimated that the proportion of bacteria 602 
in biofilms with regards to surface area (as a measure of aggregate size) in the patients treated 603 
with would be 0.7 for placebo and 0.4 for patients treated with NO. A sample size of 10 604 
participants in each treatment group would have been sufficient to determine that the NO 605 
treatment arm is superior to the control group (by reducing the proportion of biofilm bacteria) 606 
with 90% probability assuming a change from 0.7 to 0.4. It was recognized that this study would 607 
have limited ability to detect important but rare treatment-related adverse events which would 608 
need to be identified in a future larger RCT.The study was ended at the end of the funding period 609 
when 6 participants had been recruited to each group. The data was analyzed according to the 610 
statistical plan despite the lower than expected recruitment. 611 
 612 
Inclusion and exclusion criteria 613 
Adolescents and young adults with cystic fibrosis were eligible for inclusion if aged 12 or above 614 
colonized with P. aeruginosa confirmed on sputum sample. Patients were excluded for 615 
colonization with Burkholderia cepacia; known hypersensitivity to the antibiotics used in the 616 
study; other known contraindications to the antibiotics to be used in the study including known 617 
aminoglycoside related hearing/renal damage; patients requiring non-invasive ventilation; 618 
patients who had a pneumothorax; patients who were admitted for specific treatment of 619 
nontuberculous mycobacteria; patients who could not tolerate nasal cannula e.g. those who could 620 
not breathe through their nose; patients who had nasal polyposis causing significant blockage of 621 
the nasal passages; adolescents not Gillick competent (and therefore not able to give their own 622 
assent in addition to parental consent); patients not likely to survive the time period of the study 623 
washout period (4 months from enrolment); treatment with an investigational drug or device 624 
within the last 3 months prior to enrolment; patients who were pregnant (a pregnancy test was 625 
carried out for females of 11 years and above); and immediate families of investigators or site 626 
personnel directly affiliated with the study. Immediate family is defined as child or sibling, 627 
whether biological or legally adopted. 628 
 629 
Study intervention and randomization 630 
Nitric oxide gas (10 ppm, INOmax 400 ppm mol/mol inhalation gas, INO Therapeutics UK), 631 
delivered via INOvent, Ikaria Inc., Hampton, NJ, USA, supplied by INO Therapeutics UK), or 632 
identically delivered placebo (air or air/oxygen mix) was administered via nasal cannulae to 12 633 
participants admitted for intravenous (IV) antibiotics to treat pulmonary exacerbations. The study 634 
intervention was administered by inhalation via nasal cannula for 8 hours overnight for the first 635 
5-7 days of IV antibiotic therapy. This dose was based on extrapolation from in vitro work, also 636 
informed by the low dose used in hypoxic respiratory failure associated with evidence of 637 
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pulmonary hypertension in preterm infants. Electrochemical measurement of NO gas released in 638 
solution by approximately 500 M SNP was measured to be around 390 nM NO (19) which is 639 
equivalent to 390 nmol/L, giving 8.7 uL/L or 8.7 ppm (not taking into account any adjustment 640 
due to the environmental temperature). Participants, medical and laboratory staff were blinded to 641 
treatment allocation. Block randomization with block length 2 and 4 was undertaken via an 642 
online randomization service in a 1:1 ratio to ensure concealment of treatment allocation. 643 
Participants were monitored closely by a research nurse during the overnight study intervention 644 
period and monitoring and safety data were collected.  645 
 646 
Clinical study outcomes 647 
The primary outcome was the between group difference in proportion of bacteria in biofilms (as 648 
determined by direct visualization of the biofilm by FISH (21, 58-60) and image analysis). 649 
Secondary outcomes were between group differences in CFUs and quantitative PCR (q PCR) 650 
(20), measures to assess safety including lung function (FEV1 and FVC) and health related 651 
quality of life assessment (CFQ-UK) (62).  652 
 653 
Determination of nitric oxide in sputum 654 
We attempted to determine the free NO concentrations in expectorated sputum samples 655 
following inhaled NO therapy by using a Unisense nitric oxide electrochemical probe (Unisense 656 
Nitric Oxide Microsensor, glass sensor NO-10). However, due to difficulties in equilibrating and 657 
calibrating the probe within CF sputum and insufficient volumes of sputum produced by patients 658 
to carry out NO measurement alongside FISH and molecular analyses, these data are not 659 
presented. 660 
 661 
Image analysis  662 
For the ex-vivo experiments, quantification of  P. aeruginosa biofilm thickness and biomass was 663 
made from three-dimensional (3D) CSLM stacks using the freely available COMSTAT (63) 664 
software. In order to avoid subjectivity in the selection of sample regions, treatment groups were 665 
blinded to the researchers carrying out the sample analysis. In order to specifically avoid 666 
subjective bias, sample areas selected for study were chosen in a predetermined pattern. Means 667 
and standard deviations were calculated from 5 random fields of view per treatment group.  For 668 
clinical trial samples, FIJI (//fiji.sc/Fiji) 3D object counter software was used to analyze and 669 
quantify P. aeruginosa “biovolume” analysis of confocal stacks. The range of volumes of a 670 
single P. aeruginosa cell from the literature (64) (0.16-3.67 µm
3
) was used to filter fluorescently- 671 
labeled objects in the stacks into the following groups: a) noise (all objects below single cell size, 672 
estimated as less than 0.16 µm
3
); b) single cells; c) clusters (aggregates) over 10 cells in volume; 673 
and d) clusters over 20 cells in volume. After thresholding, the volume of a P. aeruginosa cell 674 
was assessed using the 3D object counter and compared to literature values for concordance. The 675 
3D object counter was then used to record all objects in each sample and results for each of the 676 
10 image stacks per sample collated into databases and grouped for analysis. For the primary 677 
analysis, aggregated cell cell clusters containing both over 20 cells and over 10 cells in size were 678 
selected as all patients had microcolonies over this size at baseline, so changes could be seen 679 
over the timecourse of the study. There were not enough clusters greater than 40 cell size to 680 
analyse, however as the 20 cell size microcolonies were estimated using the upper limit of a PA 681 
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cell size based on literature values (3.67 um3), aggregates of >20 cells by our definition were 682 
likely to contain greater than 20 cells. 683 
Measurement of nitric oxide metabolites in blood 684 
Venous blood was collected in EDTA tubes 1 and 7 hours after starting inhaled NO/placebo 685 
therapy on day 1, and immediately separated into plasma and blood cells by centrifugation for 10 686 
min at 800 x g; aliquots of plasma and red blood cell (RBC) pellet were snap frozen in liquid 687 
nitrogen and stored at -80C until analysis. NO metabolite concentrations in plasma and RBC 688 
lysate were quantified immediately after thawing of frozen samples in the presence of excess N-689 
ethylmaleimide (in PBS, 10 mM final concentration) as described previously (65-67). Briefly, 690 
nitrite and nitrate were quantified simultaneously via high pressure liquid ion chromatography 691 
(ENO-20, Eicom) with post-column Griess diazotization following on-line reduction of nitrate to 692 
nitrite.  Total nitrosation products (including low-molecular weight S-nitrosothiols,  N-693 
nitrosamines and nitrosated proteins) were measured using group-specific de-694 
nitrosation/reduction and subsequent liberation of NO, detected using gas phase 695 
chemiluminescence (CLD77am sp, Ecophysics). NO-heme concentrations were quantified by 696 
injection of RBC lysate into an oxidizing reaction solution (ferricyanide in PBS) (67), and 697 
generated NO was quantified by gas phase chemiluminescence as above. 698 
 699 
Statistical analysis 700 
Data for the laboratory study was compared using a Mann-Whitney Rank Sum test for non-701 
normally distributed data. For the clinical study an intention-to-treat analysis was undertaken. 702 
For all outcomes the change from baseline to endpoint was calculated. The primary outcome 703 
(FISH, the number and volume of aggregates >20 cells) and microbiological and clinical safety 704 
outcomes (CFU and q-PCR) were analysed on the natural log scale.  705 
 706 
The mean difference of the treatment effect between arms during the intervention period (days 707 
5,7) and total study period (days 5,7,10, 20) was estimated by conducting linear regression using 708 
the method of generalized estimating equations (GEE) (68) to take account for longitudinal 709 
dependence (where study time points were available). Residuals were examined to assess model 710 
assumptions. Analyses were performed in Stata software, version 11. 711 
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